somatuline 120mg for s.c. injection[acromegaly, pituitary gigantism] (ソマチュリン皮下注120mg[先端巨大症・下垂体性巨人症])
teijin pharma limited - lanreotide acetate - injection
somatuline 60mg for s.c. injection [thyroid-stimulating hormone-secreting pituitary tumor] (ソマチュリン皮下注60mg[甲状腺刺激ホルモン産生下垂体腫瘍])
teijin pharma limited - lanreotide acetate - injection
somatuline 60mg for s.c. injection[acromegaly, pituitary gigantism] (ソマチュリン皮下注60mg[先端巨大症・下垂体性巨人症])
teijin pharma limited - lanreotide acetate - injection
somatuline 90mg for s.c. injection [thyroid-stimulating hormone-secreting pituitary tumor] (ソマチュリン皮下注90mg[甲状腺刺激ホルモン産生下垂体腫瘍])
teijin pharma limited - lanreotide acetate - injection
somatuline 90mg for s.c. injection[acromegaly, pituitary gigantism] (ソマチュリン皮下注90mg[先端巨大症・下垂体性巨人症])
teijin pharma limited - lanreotide acetate - injection
mytolac
boucher & muir (new zealand) limited t/a bnm group - lanreotide acetate 27.3%{relative} equivalent to lanreotide 120 mg - solution for injection - 120 mg - active: lanreotide acetate 27.3%{relative} equivalent to lanreotide 120 mg excipient: acetic acid water for injection - indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory. - the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. - the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.
mytolac
boucher & muir (new zealand) limited t/a bnm group - lanreotide acetate 27.3%{relative} equivalent to lanreotide 60mg - solution for injection - 60 mg - active: lanreotide acetate 27.3%{relative} equivalent to lanreotide 60mg excipient: acetic acid water for injection - indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory. - the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. - the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.
mytolac
boucher & muir (new zealand) limited t/a bnm group - lanreotide acetate 27.3%{relative} equivalent to lanreotide 90 mg - solution for injection - 90 mg - active: lanreotide acetate 27.3%{relative} equivalent to lanreotide 90 mg excipient: acetic acid water for injection - indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory. - the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. - the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.
cedilanid tablets
novartis pharmaceuticals uk ltd - lanatoside c - tablets
paracetamol 500mg capsules
bristol laboratories ltd - paracetamol - oral capsule - 500mg